{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:40:26Z","timestamp":1790250026164,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.phrs.2017.04.022","type":"journal-article","created":{"date-parts":[[2017,4,30]],"date-time":"2017-04-30T00:46:14Z","timestamp":1493513174000},"page":"202-212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers"],"prefix":"10.1016","volume":"121","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.04.022_bib0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1128\/JVI.40.1.268-275.1981","article-title":"Some biological properties of two new avian sarcoma viruses","volume":"40","author":"Balduzzi","year":"1981","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.phrs.2017.04.022_bib0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/JVI.42.1.143-152.1982","article-title":"Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells","volume":"42","author":"Shibuya","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1128\/JVI.41.3.833-841.1982","article-title":"Genetic structure and transforming sequence of avian sarcoma virus UR2","volume":"41","author":"Wang","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0020","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1073\/pnas.87.12.4799","article-title":"Characterization of ROS cDNA from a human glioblastoma cell line","volume":"87","author":"Birchmeier","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.022_bib0025","first-page":"37","article-title":"The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer","volume":"1795","author":"Acquaviva","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2017.04.022_bib0030","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.04.022_bib0035","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/j.1460-2075.1985.tb03847.x","article-title":"Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene","volume":"4","author":"Kornblihtt","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2017.04.022_bib0040","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1006\/jmbi.1998.2115","article-title":"An extracellular \u03b2-propeller module predicted in lipoprotein and scavenger receptors, tyrosine kinases, epidermal growth factor precursor, and extracellular matrix components","volume":"283","author":"Springer","year":"1998","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2017.04.022_bib0050","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1101\/gad.10.10.1184","article-title":"The c-ros tyrosine kinase receptor controls regionalization and differentiation of epithelial cells in the epididymis","volume":"10","author":"Sonnenberg-Riethmacher","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2017.04.022_bib0055","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-11-3351","article-title":"Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion","volume":"18","author":"Rimkunas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2017.04.022_bib0065","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1158\/1078-0432.CCR-12-0838","article-title":"Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions","volume":"18","author":"Suehara","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gcc.10207","article-title":"Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)","volume":"37","author":"Charest","year":"2003","journal-title":"Genes Chromosom. Cancer"},{"key":"10.1016\/j.phrs.2017.04.022_bib0075","doi-asserted-by":"crossref","first-page":"e15640","DOI":"10.1371\/journal.pone.0015640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2017.04.022_bib0080","doi-asserted-by":"crossref","first-page":"e28250","DOI":"10.1371\/journal.pone.0028250","article-title":"Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours","volume":"6","author":"Birch","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2017.04.022_bib0085","doi-asserted-by":"crossref","first-page":"e1003464","DOI":"10.1371\/journal.pgen.1003464","article-title":"Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types","volume":"9","author":"Giacomini","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.phrs.2017.04.022_bib0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1158\/2159-8290.CD-14-0377","article-title":"Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions","volume":"4","author":"Lovly","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2017.04.022_bib0095","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2017.04.022_bib0100","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2017.04.022_bib0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2017.04.022_bib0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0115","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2017.04.022_bib0120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0125","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.022_bib0130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2017.04.022_bib0135","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.04.022_bib0140","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.04.022_bib0145","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2017.04.022_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0155","doi-asserted-by":"crossref","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nsmb.1388","article-title":"Structural and biochemical characterization of the KRLB region in insulin receptor substrate-2","volume":"15","author":"Wu","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0170","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2017.04.022_bib0175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2017.04.022_bib0180","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1126\/science.271.5250.822","article-title":"Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases","volume":"271","author":"Rawlings","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.phrs.2017.04.022_bib0185","doi-asserted-by":"crossref","first-page":"8122","DOI":"10.1074\/jbc.270.14.8122","article-title":"Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain","volume":"270","author":"Wei","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0190","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/nsb721","article-title":"Structure and autoregulation of the insulin-like growth factor 1 receptor kinase","volume":"8","author":"Favelyukis","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0195","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2017.04.022_bib0200","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.022_bib0205","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.022_bib0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0215","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0225","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0230","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2017.04.022_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0245","doi-asserted-by":"crossref","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0250","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0255","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2017.04.022_bib0260","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0265","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0270","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2017.02.010","article-title":"Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition","volume":"55","author":"Facchinetti","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2017.04.022_bib0280","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1021\/acs.jmedchem.5b02041","article-title":"Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach","volume":"59","author":"Zhao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0285","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2017.04.022_bib0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2017.04.022_bib0295","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0300","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0305","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2017.04.022_bib0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0315","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2017.04.022_bib0320","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort","volume":"33","author":"Mazi\u00e8res","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0325","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2017.04.022_bib0330","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1093\/hmg\/ddu309","article-title":"Multiple evidence strands suggest that there may be as few as 19, 000 human protein-coding genes","volume":"23","author":"Ezkurdia","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2017.04.022_bib0335","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1021\/cb300610s","article-title":"Kinase drug discovery\u2013what\u2019s next in the field?","volume":"8","author":"Cohen","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2017.04.022_bib0340","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817304747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817304747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T16:31:23Z","timestamp":1602001883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817304747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":68,"alternative-id":["S1043661817304747"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.022","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}